argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of argenx SE (NASDAQ:ARGX) have received an average rating of “Moderate Buy” from the twenty-two ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $547.74.

A number of research firms recently weighed in on ARGX. HC Wainwright upped their price target on argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a report on Friday, July 26th. William Blair reaffirmed a “market perform” rating on shares of argenx in a research note on Monday, June 17th. Wells Fargo & Company increased their price objective on shares of argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a research note on Friday, July 26th. Piper Sandler lifted their target price on shares of argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a research report on Monday, June 24th. Finally, Robert W. Baird upped their price target on shares of argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a report on Monday, July 29th.

argenx Stock Performance

argenx stock opened at $533.00 on Friday. The company has a market cap of $31.68 billion, a P/E ratio of -94.17 and a beta of 0.62. argenx has a one year low of $327.73 and a one year high of $554.74. The business has a fifty day moving average of $512.59 and a two-hundred day moving average of $432.45.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. During the same quarter last year, the business earned ($1.69) earnings per share. Sell-side analysts predict that argenx will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Profund Advisors LLC lifted its holdings in shares of argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock valued at $418,000 after acquiring an additional 28 shares in the last quarter. Wealth Alliance lifted its stake in shares of argenx by 4.8% during the second quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after purchasing an additional 29 shares in the last quarter. Lindbrook Capital LLC boosted its position in shares of argenx by 23.1% in the first quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock worth $78,000 after buying an additional 37 shares during the period. Wahed Invest LLC grew its stake in shares of argenx by 9.6% in the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after buying an additional 40 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.